Delving into the Latest Updates on Technetium (99mTc) Mercaptoacetylglycylglycylglycine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug, Diagnostic radiopharmaceuticals

Synonyms

99mTc-mercaptoacetylglycylglycylglycine, 99mTc-mercaptoacetyltriglycine, Benzoylmercaptoacetylglycylglycylglycine

+ [9]

Target-

Action

enhancers

Mechanism

SPECT(Single-photon emission-computed tomography enhancers)

Therapeutic Areas

Urogenital DiseasesOther Diseases

Active Indication

Kidney DiseasesUrethral DiseasesCalculi+ [2]

Inactive Indication-

Originator Organization

Curium US Holdings LLC

Active Organization

Curium US Holdings LLCPDRadiopharma, Inc.

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (15 Jun 1990),

CalculiRenal InsufficiencyUrinary tract obstruction

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC15H17N3O6S

InChIKeyVDPYMEBVIDZKMD-UHFFFAOYSA-N

CAS Registry103725-47-9

The radiation exposure resulting from medical imaging is a topic of some concern. Nuclear medicine provides potentially life-saving information regarding physiological processes, and is of particular value in children where the rapid and unequivocal diagnosis of pathological concerns is essential for the health of these patients. The overall objective of this investigation is to optimize pediatric patient absorbed dose by keeping it as low as possible while maintaining excellent diagnostic quality of nuclear medicine images. This is particularly important since children are at increased risk due to the enhanced radiosensitivity of their tissues and the longer time-period over which radiation effects may manifest. Current dosimetric estimations in children are based on either animal biokinetic or pharmacokinetic data from adults due to paucity of data that exists for children. This situation will be improved through the following specific aims:
* Collect image-based pharmacokinetic (PK) data from patient volunteers in different age groups scheduled for routine nuclear medicine studies for Tc-99m mercaptoacetyltriglycine (MAG3), a radiopharmaceutical commonly used in pediatric nuclear medicine
* Pool and analyze the data for different age groups for each radiopharmaceuticals and
* Generate biokinetic models to be used in subsequent dosimetric models for the optimization of pediatric nuclear medicine procedures.
Since inadequate pharmacokinetic data currently exist in these patients, the investigators will use the data acquired in this study to establish PK models applicable to different age categories. Data on the pharmacokinetics of agents used in pediatric nuclear medicine are almost completely lacking. Internationally adopted dose coefficients (mSv/MBq) for pediatric nuclear medicine make age-dependent adjustments only for patient size and anatomical differences, while time-dependent kinetics from adult PK models are assumed due to the lack of kinetic data for children. The data obtained from this study will make it possible for the first time to determine how the PK in pediatric patients differs from adults. This will be done for Tc-99m MAG3, a radiopharmaceutical commonly used for pediatric nuclear medicine imaging. The overall hope is that results will allow the molecular imaging community to implement pediatric dose-reduction approaches that substantially improve upon current guidelines pointing to future technological advances that could yield even greater dose-reduction while simultaneously improving diagnostic image quality.

Start Date02 Jan 2018

Sponsor / Collaborator

The Children's Hospital Corp.

[+3]

NCT02975986

/ WithdrawnNot ApplicableIIT

Renal Uptake of Fatty Acids (FFA) in Patients With Idiopathic Uric Acid Nephrolithiasis (IUAN)

The investigators will test the hypothesis that renal uptake of free (i.e. non-esterified) fatty acids (FFa) is increased in iuan. To accomplish this goal the investigators will measure renal FFa uptake FFa uptake in vivo in patients with iuan and matched non-stone forming subjects via single-photon emission computed tomography (SPeCT)/CT imaging.
The definitive proof of the hypothesis rests on whether increased renal FFa uptake is demonstrable in humans with iuan.

Start Date01 Jan 2017

Sponsor / Collaborator

The University of Texas Southwestern Medical Center

[+1]

100 Clinical Results associated with Technetium (99mTc) Mercaptoacetylglycylglycylglycine

Login to view more data

100 Translational Medicine associated with Technetium (99mTc) Mercaptoacetylglycylglycylglycine

Login to view more data

100 Patents (Medical) associated with Technetium (99mTc) Mercaptoacetylglycylglycylglycine

Login to view more data

111

Literatures (Medical) associated with Technetium (99mTc) Mercaptoacetylglycylglycylglycine

01 Jun 2024·Radiological physics and technology

Feasibility study of radioactivity estimation of 99mTc and 123I-labeled radiopharmaceuticals using shielded syringes

Article

Author: Nakamura, Yuto ; Yasuno, Narumi

This study investigates the feasibility of estimating the radioactivity of radiopharmaceuticals using shielded syringes. The radioactivities of ^99mTc-MDP, ^99mTc-HMDP, ^99mTc-ECD, ^99mTc-MAG₃, and ¹²³I-IMP were measured using a dose calibrator. Correlation coefficients and regression equations were obtained from the radioactivity in the shielded and unshielded syringes. ^99mTc-MDP was also measured for residual radioactivity after the administration. The correlation coefficients of ^99mTc-MDP, ^99mTc-HMDP, ^99mTc-ECD, ^99mTc-MAG₃, and ¹²³I-IMP were r_s = 0.9998, r_s = 0.9997, r_s = 0.9999, r_s = 0.9998, and r_s = 0.9888, respectively. The regression equations were y = 0.0364x + 0.0913, y = 0.0349x + 0.0273, y = 0.0343x - 0.0018, y = 0.0522x + 0.1215, and y = 0.0383x + 0.0058, respectively. The correlation coefficient for the residual radioactivity of ^99mTc-MDP was r_s = 0.9887 and the regression equation was y = 0.1505x + 0.0853. The radioactivity of ^99mTc- and ¹²³I-labeled radiopharmaceuticals in shielded syringes was accurately measured. It was suggested that the measuring shielded syringes could provide an estimate of the actual radioactivity.

01 Dec 2019·Nuklearmedizin. Nuclear medicineQ4 · MEDICINE

Comparison of glomerular filtration rate (GFR) with Tc-99m-DTPA and tubular extraction rate (TER) with Tc-99m-MAG3 in potential living kidney donors: Feasibility of a one-day protocol

Q4 · MEDICINE

Article

Author: Jaeschke, Erika ; van der Giet, Markus ; Brenner, Winfried ; Bamm, Marita ; Rogasch, Julian M. M. ; Schatka, Imke ; Bäder, Michael ; Amthauer, Holger

Abstract:

Aim Sufficient glomerular filtration rate (GFR) is mandatory in living kidney donors (LKD) before renal transplantation (RT). Guidelines recommend exogenous GFR (e. g. Tc-99m-DTPA) besides estimated GFR by plasma creatinine (eGFR). Tc-99m-MAG3 determines split function and tubular extraction rate (TER). This study evaluated a time-efficient one-day protocol for DTPA and MAG3 in potential LKD. Methods Retrospective analysis of 82 consecutive potential LKD (female, 52; age, 54 [19–73] a). DTPA GFR (Fleming formula) with blood sampling 169 (147–205) min post injection of 27 (18–59) MBq Tc-99m-DTPA. 199 (181–219) min after DTPA injection, same-day renal scintigraphy with 105 (65–150) MBq MAG3 followed (TER according to Bubeck). Sufficient GFR for RT was defined age- and sex-dependent based on British guidelines, normal TER at 70 % of age-dependent average. In 15 separate potential LKD, a blank blood sample before MAG3 injection allowed estimation of remaining DTPA counts and resulting TER error. Results Remaining Tc-99m-DTPA blood counts during sampling for MAG3 led to median TER underestimation by 12 (IQR, 8–15) ml/min/1.73 m2. Before blood count correction, 16/82 patients had reduced TER despite sufficient GFRFleming in 13/16 patients. After correction, TER remained reduced in 9/82 patients who all had sufficient GFRFleming. 10/82 patients had insufficient eGFR (CKD-EPI) but sufficient GFRFleming. Correlation coefficient for TER and GFRFleming was ρ = 0.76, for eGFR and GFRFleming ρ = 0.61, and for TER and eGFR ρ = 0.55. Conclusion A one-day protocol for Tc-99m-DTPA GFR and MAG3 dynamic imaging is feasible. If TER is calculated, the proposed method for blood count correction may be applied. However, relevance of the TER remains questionable due to frequent discordance to GFR.

01 Sep 2015·Seminars in nuclear medicineQ2 · MEDICINE

Pitfalls and Limitations of Radionuclide Renal Imaging in Adults

Q2 · MEDICINE

Review

Author: Keramida, Georgia ; James, Jacqueline M ; Prescott, Mary C ; Peters, Adrien Michael

To understand pitfalls and limitations in adult renography, it is necessary to understand firstly the physiology of the kidney, especially the magnitude and control of renal blood flow, glomerular filtration rate and tubular fluid flow rate, and secondly the pharmacokinetics and renal handling of the three most often used tracers, Tc-99m-mercaptoacetyltriglycine (MAG3), Tc-99m-diethylene triamine pentaacetic acid (DTPA) and Tc-99m-dimercaptosuccinic acid (DMSA). The kidneys may be imaged dynamically with Tc-99m-MAG3 or Tc-99m-DTPA, with or without diuretic challenge, or by static imaging with Tc-99m-DMSA. Protocols are different according to whether the kidney is native or transplanted. Quantitative analysis of dynamic data includes measurement of renal vascularity (important for the transplanted kidney), absolute tracer clearance rates, differential renal function (DRF) and response to diuretic challenge. Static image reveals functional renal parenchymal damage, both focal and global, is useful in the clinical management of obstructive uropathy, renal stone disease and hypertension (under angiotensin converting enzyme inhibition), and is the preferred technique for determining DRF. Diagnosis based on morphological appearances is important in transplant management. Even though nuclear medicine is now in the era of hybrid imaging, renal imaging remains an important subspecialty in nuclear medicine and requires a sound basing in applied physiology, the classical supporting discipline of nuclear medicine.

100 Deals associated with Technetium (99mTc) Mercaptoacetylglycylglycylglycine

Login to view more data

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Kidney Diseases	Japan	PDRadiopharma, Inc.	19 Jan 1994
Urethral Diseases	Japan	PDRadiopharma, Inc.	19 Jan 1994
Calculi	United States	Curium US Holdings LLC	15 Jun 1990
Renal Insufficiency	United States	Curium US Holdings LLC	15 Jun 1990
Urinary tract obstruction	United States	Curium US Holdings LLC	15 Jun 1990

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SNMMI2020	Not Applicable	-	-	Tc-99m MAG3	pskzmqwlou(jfjowqqrfl) = ezymmbozav tydvfswvgs (cwmhctzxzs )	-	15 May 2020
				Furosemide (Lasix)	pskzmqwlou(jfjowqqrfl) = extljcfaot tydvfswvgs (cwmhctzxzs )
EANM2017	Not Applicable	Digestive System Disorders	49	99m Tc-MAG3 (Adult patients)	wsixudtsow(lxuzmyvqfu) = cscmbtvmso muxdjxpuop (eqdaondkni )	Negative	11 Sep 2017
				99m Tc-MAG3 (Pediatric patients)	wsixudtsow(lxuzmyvqfu) = geqmbgwjbr muxdjxpuop (eqdaondkni )
SNMMI2017	Not Applicable	Hydronephrosis	-	F-15 furosemide Tc9Tc99m-MAG3 (F-15 Renogram with Tc99m-MAG3)	nfchbokllt(fobldihlpd) = yungddntwb owjjndzdwp (mgdhtdhqbf ) View more	-	24 May 2017
EANM2016	Not Applicable	-	10	Tc-MAG3 (Newborn patients)	vaenlfhjjc(wgtjdjknaz) = cflxoadofq htgkucimab (ginldyowni ) View more	-	21 Sep 2016
				Tc-MAG3 (1-year-old patients)	vaenlfhjjc(wgtjdjknaz) = qydaqazpnh htgkucimab (ginldyowni ) View more
SNMMI2014	Not Applicable	-	-	99 Tc m -MAG3 (Phantom 1)	swkmkwdapn(eomydioomd) = dgyiuaevdx ztnsywrtcc (mscajufdln, 46 - 60)	-	05 Nov 2014
				99 Tc m -MAG3 (Phantom 2)	swkmkwdapn(eomydioomd) = evogccejvm ztnsywrtcc (mscajufdln, 34 - 43)
EANM2010	Not Applicable	Visible Lesion \| Vesico-Ureteral Reflux	-	mercaptoacetyltriglycine (Fluoroscopic cystourethrography (FC))	ktucyruhds(blhpdbvoqh) = frormyfqub zjkmlylezr (trhfxzfhpp )	Positive	10 Oct 2010
				mercaptoacetyltriglycine (Tc-99m MAG3 scintigraphy)	rimfaowrzd(glyhurxdlu) = tldidtqezx exbucnuvtb (nfvbnrurbo )
EANM2007	Not Applicable	Visible Lesion	29	Tc-99m-Mercaptoacetyltriglycine	rrwgjnrrym(aslzoyflfq) = fykoyribfc ubsjxfwngj (fghjpaysxb )	-	15 Oct 2007
				Tc-99m-Dimercaptosucsinic Acid	rrwgjnrrym(aslzoyflfq) = hgycesihop ubsjxfwngj (fghjpaysxb )
EANM2007	Not Applicable	-	18	Tc-MAG-3 (Control (normothermic))	umjvnkamff(ofzupcgywc) = rntxmlviix bkgqmqrczx (mxwlxwkgxu ) View more	-	15 Oct 2007
				Tc-MAG-3 (Hyperthermic (2°C higher))	umjvnkamff(ofzupcgywc) = ozkxdpxeih bkgqmqrczx (mxwlxwkgxu ) View more